Shutdown Notice: Unfortunately I have shut down the Earnings Calls app and website. My data provider shut down their service and I couldn't find a viable alternative. If you purchased the iPhone app and feel like you didn't get your money's worth, please request a refund via the App Store. As a replacement, many brokerage services are adding earnings calls to their apps (like Robinhood, for example) or try Earningscast. Thank you to everyone who supported and enjoyed Earnings Calls, I'm sorry to let you down. – Justin Thiele

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company’s product candidates include Mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529 and coltuximab ravtansine that are in Phase II clinical trials for the treatment of non-Hodgkin lymphoma; IMGN779 that is in Phase I clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of AML. ImmunoGen, Inc. has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Roche; Sanofi; Merck; and Takeda, as well as research agreement with CytomX Therapeutics, Inc. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Read More

IMGN Conference Calls / Webcasts:

Date Time (Eastern) Title
  2/17/17 8:00 am ImmunoGen Inc Earnings (Q2 2017)
  10/28/16 8:00 am ImmunoGen Inc Earnings (Q1 2017)
  8/04/16 8:00 am ImmunoGen Inc Earnings (Q4 2016)
  10/27/15 8:00 am ImmunoGen Inc Earnings (Q1 2016)
  7/31/15 8:00 am ImmunoGen Inc Earnings (Q4 2015)
  1/30/15 8:00 am ImmunoGen Inc Earnings (Q2 2015)
Appstore
StockTwits